-
Listing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLer maisSeamless listing, trading, clearing and settlement for fixed income
-
Trading
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLer mais
Seamless listing, trading, clearing and settlement for fixed income
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLer mais
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLer maisEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Ler maisThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperNext generation of indicesLer maisThis white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Ler maisShaping capital markets for future generations
EnterNext welcomes TxCell on Euronext's market in Paris
14/04/2014
Damian Marron, CEO of TxCell, opens the European trading day in Paris.
TxCell is a biotechnology group that specializes in developing customized cell immunotherapy using antigen-specific regulatory T cells (Ag-Tregs) and for the treatment of severe chronic inflammatory and autoimmune diseases.
At the end of 2013, TxCell has a portfolio of 4 products including 1 in phase II of development (Ovasave; treatment of the Crohn disease), 1 in phase I/II of development (Col-Treg; treatment of autoimmune uveitis), 1 in phase of preclinical development (Myelin-Treg; treatment of the progressive forms of multiple sclerosis) and 1 in research phase (HSP60-Treg).